Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.

ABSTRACT:

Objectives

To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation.

Design

This was a Phase II randomized, partially double blinded, 2x2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an additional 12 wk.

Setting

The Weill-Cornell General Clinical Research Center.

Participants

Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and > 400 CD4+ T cells/microl.

Interventions

An HIV canarypox vaccine (vCP1452) and vaccine

SUBMITTER: Smith KA 

PROVIDER: S-EPMC1783674 | biostudies-literature | 2007 Jan

REPOSITORIES: biostudies-literature